Shareholder Sues Life Science Co. Over $118M Merger

Law360, New York (September 25, 2012, 11:38 PM EDT) -- An investor in gene sequencing company Complete Genomics Inc. filed a putative class action on Thursday in California challenging a proposed $118 million takeover by the U.S. subsidiary of rival BGI-Shenzhen, saying Complete was being sold for a “fire-sale price.”

The deal, which was announced Sept. 17, values Complete at $3.15 a share. According to the Mountain View, Calif.-based company, the price is a 54 percent premium over Complete's closing price of $2.04 on June 4, the last day of trading before a previous temporary trading...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.